Formycon Successfully Places EUR 70 Million Bond Amid High Demand

Formycon AG has increased its bond issuance volume from EUR 50 million to EUR 70 million due to significant oversubscription. The corporate bond, spanning 2025 to 2029, attracted considerable interest, leading to its full placement on the capital market. The interest rate was set at EURIBOR plus a 7.00% margin, the lower end of the marketing range.

The bond's overwhelming demand primarily stemmed from institutional investors both in Germany and internationally, with retail investors also participating through Deutsche Börse’s DirectPlace platform. Formycon’s successful bond placement creates a diversified financing base to support its growth strategy, focusing on expanding its biosimilar product portfolio.

The bond will trade on the Frankfurt Stock Exchange from June 30, 2025. Formycon plans additional trading on Euronext ABM within six months. This strategic move underlines Formycon's commitment to advancing its position in the biosimilars market.